For the quarter ending 2025-09-30, BJDX had -$1,360,808 decrease in cash & cash equivalents over the period. -$1,359,793 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,597,632 | -3,821,039 |
| Depreciation expense | 10,624 | 36,143 |
| Stock-based compensation expense | 183 | -251 |
| Amortization of right-of-use asset | 21,000 | 54,105 |
| Write-off and impairment of property and equipment | 36,574 | 495 |
| Deferred offering costs | 101,170 | 0 |
| Prepaid expenses and other current assets | -171,727 | -291,460 |
| Other non-current assets | -13,437 | -13,093 |
| Accounts payable | 52,345 | -36,305 |
| Accrued expenses and other current liabilities | 33,119 | 223,387 |
| Non-cash interest expense for notes payable | 0 | 0 |
| Net cash used in operating activities | -1,359,793 | -3,238,912 |
| Proceeds from issuance of common stock and prefunded warrants | 0 | 3,846,692 |
| Issuance costs related to issuance of common stock | 0 | 464,670 |
| Payment of finance lease | 1,015 | 1,979 |
| Proceeds from issuance of notes payable, net of discounts of 287,580 | 0 | 0 |
| Repayment of notes payable | 0 | 0 |
| Proceeds from exercise of class d warrants | 0 | - |
| Net cash provided by financing activities | -1,015 | 3,380,043 |
| Purchase of property and equipment | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Increase in cash and cash equivalents | -1,360,808 | 141,131 |
| Cash and cash equivalents at beginning of period | 4,301,945 | - |
| Cash and cash equivalents at end of period | 3,082,268 | - |
Bluejay Diagnostics, Inc. (BJDX)
Bluejay Diagnostics, Inc. (BJDX)